Jeff Wren - UCB SA Insider

UCB SA -- USA Stock  

USD 35.89  0.81  2.31%

Executive Vice President Neurology ? Patient Value Unit Head

Mr. Jeff Wren was Executive Vice President, Neurology Patient Value Unit Head and Member of the Executive Committee of UCB S.A. since February 2015. He joined the Company in October 2010. In his current role, he heads UCBs neurology patient value unit, neurology being one of UCBs two main therapy areas. He is responsible for the entire value chain of UCBs neurology portfolio, from development through medical, market access, sales and marketing. Before taking on his current role he was Senior Vice President UCB North America. He was responsible for providing leadership and strategic direction to all aspects of the organizations operations in both the US and Canada. Prior to this he was Vice President of UCBs Managed Markets and Trade Relations in the US and head of UCBs Canada operations. He has served as the Chairman of the Board for UCB, Inc. in the US as well as UCB Canada. He was member of the board of directors for BIO International, as well as Vicechair and executive committee member for Georgia Bio association group. He was member of the board of advisors for the Metro Atlanta Chamber of Commerce. He holds BS in Biology from Missouri Southern State University, Joplin, Missouri. At INSEAD he also completed Executive Business Program.
Age: 53  President Since 2015      
32 2 559 99 99  http://www.ucb-group.com

Management Efficiency

The company has return on total asset (ROA) of 5.76 % which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.02 % meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.9 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA (UCBJY) is traded on OTC Market in USA. It is located in Allée de la Recherche, Brussels, and employs 7,643 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add UCB SA to your portfolio

Top Management

UCB SA Leadership Team
Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Anna Richo, EVP
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman, Ph.D
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director

Stock Performance

UCB SA Performance Indicators